Swedencare AB (publ) (STO:SECARE)
Sweden · Delayed Price · Currency is SEK | Market Cap | 4.30B -21.6% |
| Revenue (ttm) | 2.70B +4.6% |
| Net Income | 49.30M -46.8% |
| EPS | 0.31 -47.1% |
| Shares Out | 159.84M |
| PE Ratio | 87.22 |
| Forward PE | 22.81 |
| Dividend | 0.28 (1.05%) |
| Ex-Dividend Date | Apr 24, 2026 |
| Volume | 96,880 |
| Average Volume | 235,865 |
| Open | 26.75 |
| Previous Close | 26.75 |
| Day's Range | 26.70 - 27.35 |
| 52-Week Range | 22.40 - 49.25 |
| Beta | 0.56 |
| RSI | 53.92 |
| Earnings Date | Apr 2, 2026 |
About Swedencare AB
Swedencare AB (publ), together with its subsidiaries, develops, manufactures, markets, and sells animal healthcare products for cats, dogs, and horses in North America, Europe, and internationally. The company offers animal nutritional supplements, treats, and grooming products for dogs under the Healthy Breeds name; pet supplements and topical products for various therapeutic areas, such as orthopedics, behavior, dermatology, odontostomatology, algology, gastroenterology, urology, nephrology, and ophthalmology under the Innovet name; and suppo... [Read more]
Financial Performance
In 2025, Swedencare AB's revenue was 2.69 billion, an increase of 6.13% compared to the previous year's 2.54 billion. Earnings were 55.50 million, a decrease of -43.88%.
Financial StatementsNews
Swedencare AB (SWDCF) Q1 2026 Earnings Call Highlights: Double-Digit Growth and Strategic Expansions
Swedencare AB (SWDCF) Q1 2026 Earnings Call Highlights: Double-Digit Growth and Strategic Expansions
Q1 2026 Swedencare AB (publ) Earnings Call Transcript
Q1 2026 Swedencare AB (publ) Earnings Call Transcript
Swedencare AB Earnings Call Transcript: Q1 2026
Double-digit organic growth and record gross margin were achieved, driven by strong European and online sales, while North America stabilized and production segments rebounded. Major new contracts, product launches, and operational efficiencies support a positive outlook for 2026.
Swedencare AB Transcript: Pre-close call
Stable demand and improved operational efficiency are driving higher margins and profitability, with strong growth in North America, Europe, and contract manufacturing. Walmart and Amazon channels show positive trends, and cost headwinds remain limited.
Swedencare AB Earnings Call Transcript: Q4 2025
Q4 2025 saw strong organic growth but disappointing profitability due to one-off costs, marketing overspend, and inventory write-offs. Improved cost controls, new product launches, and a focus on pharma and online channels are expected to drive margin recovery and growth in 2026.
Swedencare AB Earnings Call Transcript: Q3 2025
Record Q3 revenue and EBITDA were achieved, driven by strong growth in North America and Europe, major US retail expansion, and robust online sales. Outlook remains positive with double-digit growth and margin improvement expected, despite some margin pressure from marketing investments.
Swedencare AB Earnings Call Transcript: Q2 2025
Q2 2025 saw 3% sales growth and 7% organic growth, with margins impacted by the Amazon transition and delayed Walmart order. H2 is expected to deliver double-digit growth and improved profitability, driven by new launches, online momentum, and operational efficiencies.
Swedencare AB Earnings Call Transcript: Q1 2025
Q1 2025 saw 7% revenue growth and a 19.4% EBITDA margin, with strong cash flow and stable gross margin. Strategic acquisitions and new retail partnerships are set to drive double-digit organic growth for the full year, with margin improvements expected as costs normalize.
Swedencare AB Earnings Call Transcript: Q4 2024
Q4 2024 delivered record sales and EBITDA, though organic growth lagged at 4% due to NaturVet's decline. Dental and pharma segments excelled, with strong European and online performance. Outlook for 2025 is positive, with NaturVet expected to rebound and further margin improvements anticipated.
Swedencare AB Earnings Call Transcript: Q3 2024
Q3 saw 9% organic growth, with strong performance in Europe and online channels, but NaturVet's decline weighed on North America. Gross margin improved to 58%, EBITDA margin dipped due to higher marketing spend, and net debt/EBITDA fell to 2.2. 2025 is expected to bring stronger growth as new retail channels and online initiatives ramp up.
Swedencare AB Earnings Call Transcript: Q2 2024
Q2 2024 saw 10% organic growth, record sales, and margin improvement, despite softness in the veterinary channel and NaturVet brand. Strategic acquisitions, strong online and European performance, and improved inventory management are expected to drive double-digit growth and higher profitability in H2.